Top Page
Island Pharmaceuticals Ltd
(Sydney:ILA)
Island Pharmaceuticals Ltd (ILA) vs. iShares MSCI Australia ETF (EWA)
Island Pharmaceuticals Ltd Business Overview & Revenue Model
Island Pharmaceuticals Ltd Financial Statement Overview
| Breakdown | |||||
| TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 399.37K | 1.25M | 11.06K | 0.00 | 0.00 | 0.00 | Gross Profit |
| -1.30M | -1.01M | 11.06K | 0.00 | 0.00 | 0.00 | EBIT |
| -4.90M | -2.87M | -2.91M | -2.81M | -2.14M | -658.00 | EBITDA |
| -1.98M | -2.82M | 0.00 | 0.00 | 0.00 | 0.00 | Net Income Common Stockholders |
| -3.24M | -2.86M | -2.83M | -2.61M | -2.13M | -658.00 |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 3.99M | 1.66M | 2.00M | 4.79M | 6.46M | 0.00 | Total Assets |
| 4.31M | 2.56M | 2.05M | 4.90M | 6.64M | 17.00 | Total Debt |
| 0.00 | 421.97K | 0.00 | 0.00 | 0.00 | 0.00 | Net Debt |
| -3.99M | -1.24M | -2.00M | -4.79M | -6.46M | 0.00 | Total Liabilities |
| 419.62K | 1.05M | 263.85K | 580.73K | 236.83K | 674.00 | Stockholders Equity |
| 3.89M | 1.52M | 1.79M | 4.32M | 6.40M | -657.00 |
| Cash Flow | Free Cash Flow | ||||
| -2.89M | -3.16M | -2.71M | -1.88M | -938.24K | -16.00 | Operating Cash Flow |
| -2.89M | -3.16M | -2.71M | -1.88M | -938.24K | -16.00 | Investing Cash Flow |
| 0.00 | 0.00 | 0.00 | 0.00 | 77.37K | 0.00 | Financing Cash Flow |
| 5.88M | 2.79M | -171.36K | 0.00 | 7.30M | 0.00 |
Island Pharmaceuticals Ltd Technical Analysis
Island Pharmaceuticals Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $5.34B | 3.27 | -45.10% | 3.30% | 16.80% | 0.02% | |
47 Neutral | AU$43.68M | ― | -143.22% | ― | ― | -4.06% | |
| $41.45M | ― | -55.44% | ― | ― | ― | ||
| $1.73M | ― | -119.28% | ― | ― | ― | ||
| $233.39M | ― | -31.16% | ― | ― | ― | ||
43 Neutral | AU$87.95M | ― | ― | ― | -33.01% | ||
40 Underperform | AU$88.79M | ― | -85.35% | ― | 315.11% | 51.16% |
Island Pharmaceuticals Ltd Corporate Events
Island Pharmaceuticals Ltd has completed the Phase 2a/b PROTECT trial for its antiviral drug ISLA-101, aimed at treating dengue fever. The trial’s 2b cohort showed promising results, with the drug achieving target blood level concentrations in all participants, suggesting its potential effectiveness. The company also raised $1.94 million, bolstering its cash reserves to $4.82 million, which supports its ongoing clinical and strategic initiatives. The results of this trial could significantly impact Island Pharmaceuticals’ position in the antiviral drug market and provide value to shareholders.
Island Pharmaceuticals Ltd has concluded the follow-up phase of its Phase 2a/b PROTECT clinical trial for ISLA-101, aimed at treating dengue fever. The trial, which includes both preventative and therapeutic arms, has shown promising results with the desired blood concentration levels achieved in all participants. The company expects to receive virus level data by the end of the month, with high-level unblinded results anticipated in May. This progress could strengthen Island’s position in the antiviral market and enhance future regulatory engagements.
Island Pharmaceuticals Ltd announced the cessation of 203,802 securities, which expired without exercise or conversion on January 1, 2025. This cessation of securities could impact the company’s capital structure and may influence investor perceptions regarding the company’s strategic financial management.
Island Pharmaceuticals Limited has announced that Dr. David Charles Foster has ceased to be a substantial holder in the company as of March 19, 2025. This change in substantial holding is due to the exercise of options and a subsequent dilution of shares, affecting the voting securities of the company. The announcement highlights changes in relevant interests and associations, which may impact the company’s shareholder structure and voting dynamics.
Island Pharmaceuticals Limited has announced a change in the substantial holding of its shares by Dr. William James Garner. The change involves an increase in the number of fully paid ordinary shares held by Dr. Garner, from 28,386,852 to 33,198,166, resulting in a decrease in his voting power from 18.42% to 15.79%. This adjustment is attributed to a private placement and subsequent dilution, reflecting a strategic shift in the company’s shareholder structure.
Island Pharmaceuticals Ltd announced that its CEO, Dr. David Foster, will present at two upcoming conferences in Singapore and Hong Kong, showcasing the company’s progress with its Phase 2a/b PROTECT clinical trial for ISLA-101, targeting dengue fever. These events offer the company a platform to engage with institutional investors and strategic partners, potentially impacting its market positioning and stakeholder relationships.
Island Pharmaceuticals Ltd has successfully raised $2.72 million through the exercise of options, reflecting strong shareholder confidence in the company’s clinical trial pathway. The funds will be used to support ongoing clinical trials for ISLA-101, aimed at combating dengue fever. The completion of subject dosing for the Phase 2b therapeutic arm of the PROTECT clinical trial was achieved in February, with a clinical update expected in April 2025. This development is significant as dengue fever is a fast-growing global threat, and the company’s efforts to address this issue are bolstered by the financial backing of its shareholders.
Island Pharmaceuticals Ltd announced the cessation of 147,619 options expiring on March 14, 2025, due to their expiration without exercise or conversion. This announcement reflects the company’s compliance with ASX listing rules, which require notification of such security cessations. The expiration of these options may impact the company’s financial structure and stakeholders’ interests, as it involves the cessation of potential equity securities.
Island Pharmaceuticals Ltd has announced a change in the director’s interest, with Phillip Lynch exercising 80,000 options at $0.06 each, valued at $4,800. This change increases Lynch’s holdings to 340,000 fully paid ordinary shares and maintains his 3,000,000 options, potentially impacting the company’s governance and shareholder dynamics.
Island Pharmaceuticals Ltd announced the issuance of new securities as a result of options being exercised or other convertible securities being converted. This move is part of the company’s strategic efforts to enhance its financial flexibility and support its ongoing projects. The announcement reflects the company’s proactive approach to managing its capital structure, which could have implications for its market positioning and stakeholder interests.
Island Pharmaceuticals Ltd has announced the quotation of new securities on the ASX, following the exercise of options or conversion of other convertible securities. This move is part of the company’s strategy to enhance its financial flexibility and support its ongoing projects, potentially impacting its market position and offering new opportunities for stakeholders.
Island Pharmaceuticals Ltd has announced a change in the director’s interest, specifically regarding Dr. David Foster’s securities. The change involves the exercise of options, resulting in an increase in the number of fully paid ordinary shares held by Dr. Foster. This adjustment in the director’s holdings reflects strategic financial decisions that could influence the company’s market position and investor confidence.
Island Pharmaceuticals Ltd has announced the quotation of 2,218,234 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of March 5, 2025. This move is part of the company’s strategy to enhance its market presence and potentially increase its capital, which could have significant implications for its operational capabilities and stakeholder interests.
Island Pharmaceuticals Limited has issued 251,366 fully paid ordinary shares to service providers as a substitute for cash payments. This strategic move is part of the company’s compliance with the Corporations Act, potentially impacting its financial operations by conserving cash resources and aligning with regulatory requirements.
Island Pharmaceuticals Limited has announced the issuance of 72,794 ordinary fully paid shares to a service provider as a non-cash consideration. This move is part of the company’s strategy to manage its financial resources effectively, potentially impacting its operational flexibility and market positioning.
Island Pharmaceuticals Limited announced the issuance of 178,572 ordinary fully paid shares to a service provider in lieu of cash consideration. This move is part of the company’s strategy to manage its financial operations and could impact its market positioning by potentially enhancing liquidity and stakeholder engagement.
Island Pharmaceuticals Limited reported a 32.8% increase in its net loss for the half-year ending December 31, 2024, amounting to $1,533,422. Despite the financial loss, the company’s net tangible assets per ordinary security improved from 1.20 cents to 2.14 cents, indicating a stronger asset base. The company did not declare any dividends for the current or previous financial periods, reflecting a focus on reinvestment in its operations.
Island Pharmaceuticals Limited has announced the issuance of 1,704,030 fully paid ordinary securities, which will be quoted on the ASX. This move is part of the company’s strategy to enhance its financial positioning and operational capacity, potentially impacting its market presence and offering new opportunities for stakeholders.
Island Pharmaceuticals Limited has announced a change in the substantial holding of shares by Jason Alan Carroll. As of February 19, 2025, Carroll increased his voting power in the company from 14.16% to 16.25%, primarily through an option conversion that added 5.6 million shares to his holdings. This change in shareholding reflects Carroll’s continued investment in the company, potentially impacting the company’s strategic direction and influencing its control dynamics.
Island Pharmaceuticals Ltd announced the quotation of 6,061,528 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of February 19, 2025. This move is part of the company’s strategy to enhance its capital structure and potentially increase market engagement. The issuance of these securities may impact Island Pharmaceuticals’ market positioning and stakeholder confidence.
Island Pharmaceuticals Ltd has announced the issuance of 3,000,000 unquoted equity securities, specifically options expiring on various dates at various prices. This issuance is part of an employee incentive scheme and is not intended for quotation on the ASX. The move reflects the company’s efforts to incentivize its employees and align their interests with corporate growth, potentially strengthening its position in the pharmaceutical industry.
Island Pharmaceuticals Ltd has announced a change in the director’s interest notice involving Phillip Lynch, who is associated with Lynch Thinking Investments Pty Ltd. Phillip Lynch has been issued 3,000,000 options, exercisable at $0.15 and expiring on 10 February 2028, with vesting conditions set for 2026 and 2027. This issuance was approved at an extraordinary general meeting held on 28 January 2025, and it reflects a strategic move by the company to align its interests with key stakeholders, potentially impacting its market dynamics and stakeholder engagement.
Island Pharmaceuticals announced the successful completion of patient dosing in the Phase 2b clinical trial of ISLA-101, aimed at treating dengue fever. The trial, part of the larger PROTECT study, seeks to evaluate the drug’s efficacy in reducing virus levels and symptoms in infected individuals. Following promising results from the Phase 2a trial, which focused on the drug’s preventative capabilities, the company has now moved forward with the therapeutic application of ISLA-101. High-level results from this phase are expected in the coming weeks, which could significantly impact the company’s market positioning and offer a potential solution to a major unmet healthcare need.
Island Pharmaceuticals Ltd announced the application for quotation of 1,733,623 ordinary fully paid securities on the ASX, reflecting the conversion of options or convertible securities. This move could bolster the company’s financial position and market presence, potentially benefiting stakeholders by enhancing liquidity and investment appeal.
Island Pharmaceuticals Ltd has announced that it currently has 27,319,837 listed options (ASX: ILAO) expiring on March 14, 2025, with an exercise price of $0.06 per option. The company advises holders of these options on how to exercise them before the expiration date. This announcement is significant for stakeholders, as it impacts the company’s financial operations and could affect investor decisions leading up to the expiration of these options.